Sign in to enjoy up to 20% OFF or Register
  •  
[email protected]
Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others
+1 800-931-7508 [email protected]
Sign in to enjoy up to 20% OFF

[CAS NO. 2353-33-5]  Decitabine

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2353-33-5]

Catalog
HY-A0004
Brand
MCE
CAS
2353-33-5

DESCRIPTION [2353-33-5]

Overview

MDLMFCD00043011
Molecular Weight228.21
Molecular FormulaC8H12N4O4
SMILESO[C@H]1C[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO

For research use only. We do not sell to patients.

62 Publications Citing Use of MCE


Summary

Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis . Decitabine has potent anticancer activity [1] [2] .


IC50 & Target

DNMT1

DNMT3A

DNMT3B


In Vitro

Decitabine treatment significantly inhibits cell growth of SNU719, NCC24 and KATOIII 96 hours after exposure to decitabine. Decitabine induces G2/M arrest and apoptosis in EBVaGC, inhibits invasion ability, and up-regulates E-cadherin expression for EBVaGC [1] .
Only high concentrations (10 µM) Decitabine (0.1-1 μM; 24-72 hours) results in a G2 phase arrest, which is accompanied by a reduction of cells in G1 phase [3] .
Decitabine up-regulates DCTPP1 and dUTPase expression in HeLa cells [4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis [1]

Cell Line: HCT116 cells
Concentration: 0.1, 1, 10 µM
Incubation Time: 24, 48, 72 hours
Result: Only high drug concentrations (10 µM) resulted in a G2 phase arrest, which was accompanied by a reduction of cells in G1 phase.

In Vivo

Decitabine (1.0 mg/kg, p.o.) in combination with tetrahydrouridine (THU) causes severe toxicity occurs in female CD-1 mice, and results in an increased sensitivity to decitabine toxicity correlating with decitabine plasma levels [5] .
Decitabine (1.0 mg/kg; i.p.; once daily for 5 consecutive days) leads to regression of EL4 tumors established in C57BL/6 Mice [7] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice (bearing EL4 cells) [6]
Dosage: 1.0 mg/kg
Administration: Intraperitoneal injection; once daily for 5 consecutive days
Result: Caused continuous tumor regression even after Decitabine treatment was stopped.

Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT04283526 Novartis Pharmaceuticals|Novartis
Primary Myelofibrosis|Myelofibrosis|PMF|Post-Essential Thrombocythemia Myelofibrosis|Post-Polycythemia Vera Myelofibrosis
November 30, 2020 Phase 1
NCT01690507 Chinese PLA General Hospital|Navy General Hospital, Beijing
MDS|AML
November 2012 Phase 1|Phase 2
NCT03233724 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Carcinoma, Non-Small-Cell Lung|Lung Cancer|Non-Small Cell Lung Cancer|Carcinoma, Esophageal|Malignant Pleural Mesotheliomas
April 11, 2018 Phase 1|Phase 2

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)


Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL ( 219.10 mM )

H 2 O : 20 mg/mL ( 87.64 mM ; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.3819 mL 21.9096 mL 43.8193 mL
5 mM 0.8764 mL 4.3819 mL 8.7639 mL
10 mM 0.4382 mL 2.1910 mL 4.3819 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: PBS

    Solubility: 10 mg/mL (43.82 mM); Clear solution; Need ultrasonic

  • 2.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution

  • 4.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution

* All of the co-solvents are available by MCE.


Synonyms

1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-
s-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-
4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
5-Aza-2′-deoxycytidine
5-Azadeoxycytidine
2-Desoxy-5-azacytidine
2′-Deoxy-5-azacytidine
Decitabine
NSC 127716
DAC
Dacogen
β-Decitabine
5-Aza-2-deoxycytidine
4-Amino-1-(2-deoxy-β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
A 2232
NSC127716

Information
Shipping
Privacy notice
Terms of Service
About us
Contact us
Customer services
Search
Custom Synthesis
My account
My account
Orders
Addresses
Shopping cart
Pay
Powered by Arctom Copyright © 2025 Arctom. All rights reserved.